Compounds > chloroquine
Page last updated: 2024-10-24

chloroquine and Viral Diseases

chloroquine has been researched along with Viral Diseases in 8 studies

Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.

Research Excerpts

ExcerptRelevanceReference
"Chloroquine (CHQ) is a cheap, relatively well tolerated drug initially developed for the treatment of malaria in the 1930s."4.84Chloroquine: novel uses & manifestations. ( Cooper, RG; Magwere, T, 2008)
"Effective treatment of retinal diseases with adeno-associated virus (AAV)-mediated gene therapy is highly dependent on the proportion of successfully transduced cells."2.66Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy. ( Barnard, AR; Chandler, LC; MacLaren, RE; McClements, ME; Xue, K; Yusuf, IH, 2020)
"Chloroquine is a 9-aminoquinoline known since 1934."2.42Effects of chloroquine on viral infections: an old drug against today's diseases? ( Boelaert, JR; Cassone, A; Cauda, R; Majori, G; Savarino, A, 2003)
" A physiologically based pharmacokinetic model with detailed respiratory physiology was used to predict regional airway exposure and optimize dosing regimens."1.72Translational Modeling of Chloroquine and Hydroxychloroquine Dosimetry in Human Airways for Treating Viral Respiratory Infections. ( Calvino-Martin, F; Hoeng, J; Kolli, AR, 2022)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19902 (25.00)18.7374
1990's1 (12.50)18.2507
2000's3 (37.50)29.6817
2010's0 (0.00)24.3611
2020's2 (25.00)2.80

Authors

AuthorsStudies
Kolli, AR1
Calvino-Martin, F1
Hoeng, J1
Chandler, LC1
Yusuf, IH1
McClements, ME1
Barnard, AR1
MacLaren, RE1
Xue, K1
Cooper, RG1
Magwere, T1
Savarino, A1
Boelaert, JR1
Cassone, A1
Majori, G1
Cauda, R1
Rolain, JM1
Colson, P1
Raoult, D1
Jung, A1
Singh, MM1
Jajoo, U1
Frame, JD1
Baldwin, JM1
Gocke, DJ1
Troup, JM1
de Duve, C1
de Barsy, T1
Poole, B1
Trouet, A1
Tulkens, P1
Van Hoof, F1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prophylaxis With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19)[NCT04627467]Phase 23,217 participants (Actual)Interventional2020-03-28Completed
A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation[NCT00819390]Phase 270 participants (Actual)Interventional2009-03-31Completed
Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19[NCT04394416]Phase 3204 participants (Anticipated)Interventional2020-06-02Active, not recruiting
Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts[NCT04652648]Phase 454 participants (Actual)Interventional2020-05-27Completed
A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome: a Strategy to Prevent Hospitalization[NCT04365582]Phase 30 participants (Actual)Interventional2020-05-07Withdrawn (stopped due to The PI decided.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Percent CD8 HLA-DR+/CD38+ From Baseline to Week 12

The baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+. (NCT00819390)
Timeframe: At pre-entry, entry, weeks 10 and 12

Interventionpercent of CD8 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants-2.0
B: Placebo Then Chloroquine for Off-ART Participants-0.5
C: Chloroquine Then Placebo for On-ART Participants-3.1
D: Placebo Then Chloroquine for On-ART Participants-1.2

Change in Percent CD8 HLA-DR+/CD38+ From Baseline to Week 24 in Arm A and Arm C

The baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 22 and week 24 percent CD8 HLA-DR+/CD38+. (NCT00819390)
Timeframe: At Pre-entry, entry, Weeks 22 and 24

Interventionpercent of CD8 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants10.8
C: Chloroquine Then Placebo for On-ART Participants-2.4

Change in Percent CD8 HLA-DR+/CD38+ From Start to End of the 12-week Chloroquine Treatment Period

For Arm A: Chloroquine then Placebo for off-ART participants and Arm C: Chloroquine then Placebo for on-ART participants, the baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+. For Arm B: Placebo then Chloroquine for off-ART participants and Arm D: Placebo then Chloroquine for on-ART participants, the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+ was subtracted from the mean of week 22 and week 24 percent CD8 HLA-DR+/CD38+. (NCT00819390)
Timeframe: For Arms A and C: Pre-entry, entry, weeks 10 and 12. For Arms B and D: Weeks 10, 12, 22 and 24

Interventionpercent of CD8 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants-2.0
B: Placebo Then Chloroquine for Off-ART Participants1.5
C: Chloroquine Then Placebo for On-ART Participants-3.1
D: Placebo Then Chloroquine for On-ART Participants-2.9

Change in Percent CD8 HLA-DR+/CD38+ From Week 12 to Week 24

The mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+ is subtracted from the mean of the week 22 and week 24 percent CD8 HLA-DR+/CD38+ (NCT00819390)
Timeframe: At Weeks 10, 12, 22 and 24

Interventionpercent of CD8 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants5.5
B: Placebo Then Chloroquine for Off-ART Participants1.5
C: Chloroquine Then Placebo for On-ART Participants-0.1
D: Placebo Then Chloroquine for On-ART Participants-2.9

Change in Total CD4 T Cell Count From Baseline to Week 12

Baseline CD4 count (mean of pre-entry and entry CD4 count) is subtracted from the mean of week 10 and week 12 CD4 count (NCT00819390)
Timeframe: At pre-entry, entry, weeks 10 and 12

Interventioncells/mm^3 (Median)
A: Chloroquine Then Placebo for Off-ART Participants-27
B: Placebo Then Chloroquine for Off-ART Participants-11
C: Chloroquine Then Placebo for On-ART Participants-6
D: Placebo Then Chloroquine for On-ART Participants7

Fasting Lipopolysaccharides (LPS) at Entry

Results reported are for entry fasting LPS. (NCT00819390)
Timeframe: At entry

Interventionpg/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants13.68
B: Placebo Then Chloroquine for Off-ART Participants1.64
C: Chloroquine Then Placebo for On-ART Participants8.00
D: Placebo Then Chloroquine for On-ART Participants7.00

Fasting Lipopolysaccharides (LPS) at Week 12

Results reported are the week 12 fasting LPS. (NCT00819390)
Timeframe: At week 12

Interventionpg/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants14.37
B: Placebo Then Chloroquine for Off-ART Participants13.06
C: Chloroquine Then Placebo for On-ART Participants7.00
D: Placebo Then Chloroquine for On-ART Participants7.00

Fasting Lipopolysaccharides (LPS) at Week 24

Results reported are the week 24 fasting LPS. (NCT00819390)
Timeframe: At week 24

Interventionpg/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants20.54
B: Placebo Then Chloroquine for Off-ART Participants2.83
C: Chloroquine Then Placebo for On-ART Participants7.00
D: Placebo Then Chloroquine for On-ART Participants8.00

HIV-1 RNA Copies/mL at Study Entry for Off-ART Participants

Results reported are for HIV-1 RNA (copies/mL) at study entry for off-ART participants. (NCT00819390)
Timeframe: At Entry

Interventionlog10 copies/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants4.48
B: Placebo Then Chloroquine for Off-ART Participants4.42

Number of Participants With Events Grade 3 or Higher

Events included signs and symptoms, laboratory abnormalities and/or clinical events grade 3 or higher which were described by site clinician blinded to the treatment arm as definitely or possibly related to the study treatment. (NCT00819390)
Timeframe: From start of study treatment to study completion at week 28

Interventionparticipants (Number)
A: Chloroquine Then Placebo for Off-ART Participants0
B: Placebo Then Chloroquine for Off-ART Participants1
C: Chloroquine Then Placebo for On-ART Participants1
D: Placebo Then Chloroquine for On-ART Participants0

Percent CD4 HLA-DR+/CD38+ at Baseline

Baseline CD4 HLA-DR+/CD38+ is computed as the mean of pre-entry and entry CD4 HLA-DR+/CD38+. (NCT00819390)
Timeframe: At pre-entry and entry

Interventionpercent of CD4 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants8.5
B: Placebo Then Chloroquine for Off-ART Participants9.8
C: Chloroquine Then Placebo for On-ART Participants8.7
D: Placebo Then Chloroquine for On-ART Participants9.9

Percent CD4 HLA-DR+/CD38+ at Week 12

Results reported are the week 12 percentage of CD4 expressing HLA-DR+/CD38+. (NCT00819390)
Timeframe: At Week 12

Interventionpercent of CD4 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants6.5
B: Placebo Then Chloroquine for Off-ART Participants10.5
C: Chloroquine Then Placebo for On-ART Participants7.7
D: Placebo Then Chloroquine for On-ART Participants9.0

Percent CD4 HLA-DR+/CD38+ at Week 24

Results reported are the week 24 percentage of CD4 expressing HLA-DR+/CD38+. (NCT00819390)
Timeframe: At Week 24

Interventionpercent of CD4 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants11.0
B: Placebo Then Chloroquine for Off-ART Participants12.5
C: Chloroquine Then Placebo for On-ART Participants7.3
D: Placebo Then Chloroquine for On-ART Participants9.2

Percent CD8 CD38+ at Baseline

Baseline CD8 CD38+ is computed as the mean of pre-entry and entry CD8 CD38+. (NCT00819390)
Timeframe: At pre-entry and entry

Interventionpercent of CD8 expressing CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants71.0
B: Placebo Then Chloroquine for Off-ART Participants77.0
C: Chloroquine Then Placebo for On-ART Participants50.8
D: Placebo Then Chloroquine for On-ART Participants49.9

Percent CD8 CD38+ at Week 12

Results reported are the week 12 percentage of CD8 expressing CD38+. (NCT00819390)
Timeframe: At Week 12

Interventionpercent of CD8 expressing CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants71.5
B: Placebo Then Chloroquine for Off-ART Participants79.5
C: Chloroquine Then Placebo for On-ART Participants50.9
D: Placebo Then Chloroquine for On-ART Participants51.9

Percent CD8 CD38+ at Week 24

Results reported are the week 24 percentage of CD8 expressing CD38+. (NCT00819390)
Timeframe: At Week 24

Interventionpercent of CD8 expressing CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants78.0
B: Placebo Then Chloroquine for Off-ART Participants79.5
C: Chloroquine Then Placebo for On-ART Participants50.6
D: Placebo Then Chloroquine for On-ART Participants48.7

Soluble CD14 (sCD14) at Baseline

Baseline sCD14 was computed as the mean of pre-entry and entry sCD14. (NCT00819390)
Timeframe: At pre-entry and entry

Interventionmillion pg/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants1.43
B: Placebo Then Chloroquine for Off-ART Participants1.97
C: Chloroquine Then Placebo for On-ART Participants1.80
D: Placebo Then Chloroquine for On-ART Participants1.58

Soluble CD14 (sCD14) at Week 12

Results reported are the week 12 sCD14. (NCT00819390)
Timeframe: At week 12

Interventionmillion pg/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants1.53
B: Placebo Then Chloroquine for Off-ART Participants1.88
C: Chloroquine Then Placebo for On-ART Participants2.04
D: Placebo Then Chloroquine for On-ART Participants1.63

Soluble CD14 (sCD14) at Week 24

Results reported are the week 24 sCD14. (NCT00819390)
Timeframe: At week 24

Interventionmillion pg/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants1.53
B: Placebo Then Chloroquine for Off-ART Participants2.19
C: Chloroquine Then Placebo for On-ART Participants1.77
D: Placebo Then Chloroquine for On-ART Participants1.72

HIV-1 RNA Copies/mL at Study Entry for On-ART Participants

Results reported are for HIV-1 RNA at study entry for on-ART participants. (NCT00819390)
Timeframe: At Entry

,
Interventionparticipants (Number)
at or below lower limit of quantitationabove lower limit of quantitation
C: Chloroquine Then Placebo for On-ART Participants162
D: Placebo Then Chloroquine for On-ART Participants172

HIV-1 RNA Copies/mL at Week 12 for On-ART Participants

Results reported are for HIV-1 RNA at week 12 for on-ART participants. (NCT00819390)
Timeframe: At week 12

,
Interventionparticipants (Number)
at or below lower limit of quantitationabove lower limit of quantitation
C: Chloroquine Then Placebo for On-ART Participants161
D: Placebo Then Chloroquine for On-ART Participants181

HIV-1 RNA Copies/mL at Week 24 for On-ART Participants

Results reported are for HIV-1 RNA at week 24 for on-ART participants. (NCT00819390)
Timeframe: At week 24

,
Interventionparticipants (Number)
at or below lower limit of quantitationabove lower limit of quantitation
C: Chloroquine Then Placebo for On-ART Participants142
D: Placebo Then Chloroquine for On-ART Participants181

HIV-1 RNA Copies/mL at Weeks 12 and 24 for Off-ART Participants

Results reported are for HIV-1 RNA (copies/mL) at week 12 and week 24 for off-ART participants. (NCT00819390)
Timeframe: At weeks 12 and 24

,
Interventionlog10 copies/mL (Median)
Week 12Week 24
A: Chloroquine Then Placebo for Off-ART Participants4.684.69
B: Placebo Then Chloroquine for Off-ART Participants4.284.61

IL-6, Soluble TNF-rI (sTNF-rI) and D-dimer at Baseline

Baseline IL-6, sTNF-rI and D-dimer were computed as the mean of pre-entry and entry IL-6, sTNF-rI and D-dimer, respectively. (NCT00819390)
Timeframe: At pre-entry and entry

,,,
Interventionpg/mL (Median)
IL-6sTNF-rID-dimer
A: Chloroquine Then Placebo for Off-ART Participants1.651228.66286390
B: Placebo Then Chloroquine for Off-ART Participants1.621377.81328460
C: Chloroquine Then Placebo for On-ART Participants1.011316.63107890
D: Placebo Then Chloroquine for On-ART Participants1.511250.85103530

IL-6, Soluble TNF-rI (sTNF-rI) and D-dimer at Week 12

Results reported are the week 12 IL-6, sTNF-rI and D-dimer. (NCT00819390)
Timeframe: At week 12

,,,
Interventionpg/mL (Median)
IL-6sTNF-rID-dimer
A: Chloroquine Then Placebo for Off-ART Participants1.681209.50251320
B: Placebo Then Chloroquine for Off-ART Participants1.281347.06319770
C: Chloroquine Then Placebo for On-ART Participants1.151441.35126540
D: Placebo Then Chloroquine for On-ART Participants1.301304.77117890

IL-6, Soluble TNF-rI (sTNF-rI) and D-dimer at Week 24

Results reported are the week 24 IL-6, sTNF-rI and D-dimer. (NCT00819390)
Timeframe: At week 24

,,,
Interventionpg/mL (Median)
IL-6sTNF-rID-dimer
A: Chloroquine Then Placebo for Off-ART Participants1.341327.21264240
B: Placebo Then Chloroquine for Off-ART Participants1.181420.30294780
C: Chloroquine Then Placebo for On-ART Participants1.021230.21100860
D: Placebo Then Chloroquine for On-ART Participants1.271176.20124920

Percent Activation Levels of Plasmacytoid Dendritic Cells (pDC) and Myeloid Dendritic Cells (mDC) at Baseline

Baseline percent activation levels of pDC were computed as the mean of pre-entry and entry percent activation levels of pDC. Similarly, baseline percent activation levels of mDC were computed as the mean of pre-entry and entry percent activation levels of mDC. (NCT00819390)
Timeframe: At pre-entry and entry

,,,
Interventionpercentage of cells (Median)
%pDC expressing CD80+%pDC expressing CD83+%pDC expressing CD86+%pDC expressing PDL-1+%mDC expressing CD80+%mDC expressing CD83+%mDC expressing CD86+%mDC expressing PDL-1+
A: Chloroquine Then Placebo for Off-ART Participants0.0345.489.122.521.0438.6096.299.82
B: Placebo Then Chloroquine for Off-ART Participants0.0336.159.356.130.8339.9497.5216.37
C: Chloroquine Then Placebo for On-ART Participants0.1319.9110.964.481.3148.1796.114.58
D: Placebo Then Chloroquine for On-ART Participants0.0723.6512.666.491.1726.0895.388.28

Percent Activation Levels of Plasmacytoid Dendritic Cells (pDC) and Myeloid Dendritic Cells (mDC) at Week 12

Results reported are the week 12 percent activation levels of pDC and mDC. (NCT00819390)
Timeframe: At week 12

,,,
Interventionpercentage of cells (Median)
%pDC expressing CD80+%pDC expressing CD83+%pDC expressing CD86+%pDC expressing PDL-1+%mDC expressing CD80+%mDC expressing CD83+%mDC expressing CD86+%mDC expressing PDL-1+
A: Chloroquine Then Placebo for Off-ART Participants0.0051.907.663.740.8443.5197.9015.03
B: Placebo Then Chloroquine for Off-ART Participants0.0540.498.488.431.0336.4797.1816.32
C: Chloroquine Then Placebo for On-ART Participants0.1014.7013.937.241.4747.8395.407.10
D: Placebo Then Chloroquine for On-ART Participants0.1418.2013.645.161.0126.7595.156.09

Percent Activation Levels of Plasmacytoid Dendritic Cells (pDC) and Myeloid Dendritic Cells (mDC) at Week 24

Results reported are the week 24 percent activation levels of pDC and mDC. (NCT00819390)
Timeframe: At week 24

,,,
Interventionpercentage of cells (Median)
%pDC expressing CD80+%pDC expressing CD83+%pDC expressing CD86+%pDC expressing PDL-1+%mDC expressing CD80+%mDC expressing CD83+%mDC expressing CD86+%mDC expressing PDL-1+
A: Chloroquine Then Placebo for Off-ART Participants0.0544.5010.134.340.9441.2197.709.53
B: Placebo Then Chloroquine for Off-ART Participants0.0038.967.897.451.1233.1997.0514.84
C: Chloroquine Then Placebo for On-ART Participants0.0814.8011.795.630.7636.6596.694.13
D: Placebo Then Chloroquine for On-ART Participants0.1617.6512.886.521.3924.1492.417.49

Reviews

5 reviews available for chloroquine and Viral Diseases

ArticleYear
Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy.
    International journal of molecular sciences, 2020, Jul-14, Volume: 21, Issue:14

    Topics: Animals; Betacoronavirus; Chloroquine; Dependovirus; Genetic Therapy; Humans; Hydroxychloroquine; Im

2020
Chloroquine: novel uses & manifestations.
    The Indian journal of medical research, 2008, Volume: 127, Issue:4

    Topics: Antimalarials; Chloroquine; Humans; Malaria; Neoplasms; Virus Diseases

2008
Effects of chloroquine on viral infections: an old drug against today's diseases?
    The Lancet. Infectious diseases, 2003, Volume: 3, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute

2003
Effects of chloroquine on viral infections: an old drug against today's diseases?
    The Lancet. Infectious diseases, 2003, Volume: 3, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute

2003
Effects of chloroquine on viral infections: an old drug against today's diseases?
    The Lancet. Infectious diseases, 2003, Volume: 3, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute

2003
Effects of chloroquine on viral infections: an old drug against today's diseases?
    The Lancet. Infectious diseases, 2003, Volume: 3, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute

2003
Effects of chloroquine on viral infections: an old drug against today's diseases?
    The Lancet. Infectious diseases, 2003, Volume: 3, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute

2003
Effects of chloroquine on viral infections: an old drug against today's diseases?
    The Lancet. Infectious diseases, 2003, Volume: 3, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute

2003
Effects of chloroquine on viral infections: an old drug against today's diseases?
    The Lancet. Infectious diseases, 2003, Volume: 3, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute

2003
Effects of chloroquine on viral infections: an old drug against today's diseases?
    The Lancet. Infectious diseases, 2003, Volume: 3, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute

2003
Effects of chloroquine on viral infections: an old drug against today's diseases?
    The Lancet. Infectious diseases, 2003, Volume: 3, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute

2003
Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century.
    International journal of antimicrobial agents, 2007, Volume: 30, Issue:4

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Antiviral Agents; Bacterial Infecti

2007
Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century.
    International journal of antimicrobial agents, 2007, Volume: 30, Issue:4

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Antiviral Agents; Bacterial Infecti

2007
Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century.
    International journal of antimicrobial agents, 2007, Volume: 30, Issue:4

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Antiviral Agents; Bacterial Infecti

2007
Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century.
    International journal of antimicrobial agents, 2007, Volume: 30, Issue:4

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Antiviral Agents; Bacterial Infecti

2007
Commentary. Lysosomotropic agents.
    Biochemical pharmacology, 1974, Sep-15, Volume: 23, Issue:18

    Topics: Anti-Bacterial Agents; Antibodies; Bacterial Infections; Carrier Proteins; Chloroquine; Dextrans; DN

1974

Other Studies

3 other studies available for chloroquine and Viral Diseases

ArticleYear
Translational Modeling of Chloroquine and Hydroxychloroquine Dosimetry in Human Airways for Treating Viral Respiratory Infections.
    Pharmaceutical research, 2022, Volume: 39, Issue:1

    Topics: Administration, Inhalation; Aerosols; Algorithms; Cell Line; Chloroquine; COVID-19; Cytosol; Humans;

2022
Unexplained fever-analysis of 233 cases in a referral hospital.
    Indian journal of medical sciences, 1999, Volume: 53, Issue:12

    Topics: Adult; Antimalarials; Bacterial Infections; Chloroquine; Diagnosis, Differential; Female; Fever of U

1999
Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings.
    The American journal of tropical medicine and hygiene, 1970, Volume: 19, Issue:4

    Topics: Acute Disease; Adult; Aged; Autopsy; Back Pain; Blood; Blood Cell Count; Chloroquine; Edema; Female;

1970